Latest news with #iCRO
National Post
4 days ago
- Business
- National Post
Veranex Unveils MedTech's First Innovation CRO (iCRO)--Redefining R&D in a Capital‑Tight Market
Article content RALEIGH, N.C. — Veranex, a global provider of product development and contract research services, today introduced the industry's first Innovation CRO (iCRO) —an integrated development and research platform engineered to move medical devices and in-vitro diagnostics (IVDs) from concept to commercial success faster, with tighter budget control and a built-in path to payer adoption. Article content Introducing the world's first Innovation CRO (iCRO)—delivering safer, smarter, faster MedTech development in today's challenging capital markets. From concept to commercialization, we're redefining how medical device innovation gets done. Article content Article content Speed & Capital Efficiency – Integrated teams and workflows can cut 3–6 months per development phase and reduce budget variance 18 percent versus transactional (traditional) outsourcing. Flexible partnership tiers— Full Stack, Stage Select, and Strategic Augment —let sponsors deploy only the iCRO services they need while retaining velocity. Evidence Integration from Day One – Product design research, human factors engineering, and reimbursement strategists collaborate upfront in the iCRO model to identify data packages that resonate with regulators, investors, and payers—reducing the likelihood of late-stage pivots commonly encountered today. Device & IVD Specific Depth – Over 1,000 device & IVD programs and 2,500 clinical trials completed by a team of 800+ experts across North America, Europe, and APAC. Veranex brings deep expertise in cardiovascular, neurovascular, ophthalmology, in-vitro diagnostics and more. Regulatory & Market Access Alignment – 96 percent approval rate and proven market access pathways in 30+ countries, guided by in-house health economics analysts and payer panels. Article content 'Speed and capital efficiency are no longer competitive advantages—they are survival mandates,' said Patrick Donnelly, Chief Executive Officer, Veranex. 'Our Innovation CRO answers that mandate with excellence and rigor, integrating every critical discipline—design, engineering, preclinical, clinical, regulatory, quality, manufacturing, market access—into one accountable team that delivers validated evidence at every step.' Article content Meeting Today's Market Demands Article content The iCRO model addresses evolving industry challenges where venture investment and access to cheap capital in MedTech have dropped significantly from recent highs. Constrained teams face industry consolidation and internal capability gaps, while evolving EU MDR/IVDR and FDA requirements extend market clearance timelines. At the same time, artificial intelligence features are racing into next-generation devices, raising both regulatory scrutiny and evidence demands. In this complex landscape, today's innovators need more than traditional vendors. They need strategic partners who can deliver integrated solutions with speed and certainty. Article content 'Whether you're a seed-stage innovator or a global strategic, our iCRO partnerships enable clients to focus scarce capital on innovation while we derisk execution across multiple geographies,' said Ryan Roberts, Chief Commercial Officer, Veranex. 'We provide access to cross-functional expertise precisely where and when it's needed, accelerating progress toward critical milestones.' Article content About Veranex Article content Veranex Article content Article content Article content Article content Article content Contacts Article content Media Contact Article content Article content John W. Colby III Article content Article content Article content Article content
Business Wire
09-07-2025
- Business
- Business Wire
Median Technologies: Half Year Liquidity Contract Statement
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: Under the liquidity contract entrusted by Median Technologies (PARIS: ALMDT, FR0011049824, ALMDT, PEA/SME eligible, 'Median' or 'the Company') to TP ICAP (Europe), the following resources were listed in the liquidity account as of June 30, 2025: 60,808 shares €58,893.66 in cash Transactions during the first half 2025: For information, as of December 31, 2024, the following resources were listed in the liquidity contract: 30,559 shares €134,615.99 in cash For information, as of May 4th, 2020, when the new liquidity contract was set up, the following resources were listed in the liquidity account: 4,404 shares €173,829.64 in cash TP ICAP (Europe) is authorized and regulated by the Autorité de Contrôle Prudentiel (ACPR) and the Autorité des Marchés Financiers (AMF). The daily transaction table is provided in the appendix to this press release. About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis ®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit APPENDIX
Business Wire
07-07-2025
- Business
- Business Wire
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of June 30, 2025
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT): (*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF's General Regulations About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit
Yahoo
10-06-2025
- Business
- Yahoo
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2025
Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. SOPHIA ANTIPOLIS, France, June 10, 2025--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares 19,347,033 Number of real voting rights* (excluding treasury shares**) 19,280,095 Theoretical number of voting rights* (including treasury shares**) 19,323,833 (*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF's General Regulations About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit View source version on Contacts Median Technologies Emmanuelle LeyguesVP, Corporate Marketing & Financial Communications+33 6 10 93 58 Investors - ACTIFIN Ghislaine Gasparetto+33 6 21 10 49 Press – Ulysse Communication Bruno Arabian+33 6 87 88 47 26barabian@ Nicolas Entz+33 6 33 67 31 54nentz@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
10-06-2025
- Business
- Business Wire
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2025
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT): About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit
